Biotechnology company developing neuromodulators for aesthetic and therapeutic indications.
Revance Therapeutics, Inc. is a pioneering biotechnology company focused on advancing, manufacturing, and globally commercializing neuromodulators for both aesthetic and therapeutic applications. Based in Nashville, Tennessee, the company has established itself as a leader in the field, with a robust pipeline aimed at addressing various medical needs.
Central to Revance Therapeutics' portfolio is its lead drug candidate, DaxibotulinumtoxinA for injection, which has successfully completed Phase III clinical trials for treating glabellar (frown) lines and cervical dystonia. The drug is currently in Phase II clinical trials targeting upper facial lines, dynamic forehead lines, and lateral canthal lines. Moreover, DaxibotulinumtoxinA has shown promise in Phase II trials for addressing adult upper limb spasticity and plantar fasciitis. The company is also exploring its potential for treating migraine through ongoing preclinical trials, alongside a topical program designed for multiple indications.
Revance Therapeutics is actively developing OnabotulinumtoxinA, a biosimilar to BOTOX, through a collaboration and license agreement with Viatris Inc. This strategic partnership aims to expand the availability and accessibility of effective neuromodulator treatments globally.
Founded in 1999 and initially known as Essentia Biosystems, Inc., the company rebranded as Revance Therapeutics, Inc. in April 2005. With its steadfast commitment to innovation and therapeutic advancement, Revance Therapeutics continues to pioneer new standards in neuromodulation therapy, striving to enhance patient outcomes and redefine treatment possibilities in aesthetic and therapeutic medicine.